Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014)
Insmed (INSM) recorded quarterly Non-Current Deffered Revenue of $118000.0 in Q4 2014, down 36.22% quarter-over-quarter from $185000.0 in Q3 2014, and down 68.95% on a YoY basis from $380000.0 in Q4 2013.
Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014) Analysis & Trends
Insmed's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $118000.0 for Q4 2014.
- In Q4 2014, Non-Current Deffered Revenue fell 68.95% year-over-year to $118000.0; the TTM figure through Dec 2014 stood at $118000.0 (down 68.95% YoY), while the FY2014 annual figure was $118000.0, down 68.95% from the prior year.
- Non-Current Deffered Revenue was $118000.0 for Q4 2014 at Insmed, down from $185000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $647000.0 in Q4 2012 to a low of $118000.0 in Q4 2014.
- Historically, Non-Current Deffered Revenue has averaged $382000.0 across 3 years, with a median of $380000.0 in 2013.
- The sharpest annual moves came in 2013 and 2014: Non-Current Deffered Revenue slumped 41.27% in 2013, then tumbled 68.95% in 2014.
- A 3-year view of Non-Current Deffered Revenue shows it stood at $647000.0 in 2012, then plunged by 41.27% to $380000.0 in 2013, then sank by 68.95% to $118000.0 in 2014.
- The last three Non-Current Deffered Revenue figures came in at $118000.0 (Q4 2014), $185000.0 (Q3 2014), and $250000.0 (Q2 2014), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 118,000.00 |
| Sep 30, 2014 | 185,000.00 |
| Jun 30, 2014 | 250,000.00 |
| Mar 31, 2014 | 315,000.00 |
| Dec 31, 2013 | 380,000.00 |
| Sep 30, 2013 | 449,000.00 |
| Jun 30, 2013 | 514,000.00 |
| Mar 31, 2013 | 580,000.00 |
| Dec 31, 2012 | 647,000.00 |